Form 4: Gossamer Bio Director Sandra Milligan Granted 115,000 Stock Options

Gossamer Bio, Inc. Director Sandra Milligan was granted 115,000 stock options with an exercise price of $1.36 as part of her compensation.

Summary

• Sandra Milligan, a Director of Gossamer Bio, Inc. (GOSS), was granted 115,000 stock options.
• The transaction date for this grant was June 25, 2025.
• The exercise price for these stock options is $1.36 per share.
• The options have an expiration date of June 24, 2035.
• The award was made pursuant to the company's Non-Employee Director Compensation Program.
• The options will become fully vested and exercisable on the first anniversary of the grant date (June 25, 2026) or the next annual meeting of the Issuer's stockholders, whichever occurs first, contingent on Ms. Milligan's continued service on the board.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the stock option grant aligns the director's interests with shareholders, which is a standard and generally beneficial corporate governance practice. It is a routine compensation event rather than a significant new development.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The options are part of a structured Non-Employee Director Compensation Program, indicating a standard approach to governance and compensation.

Future Outlook

The stock options granted to Director Sandra Milligan are subject to future vesting, which will occur on the first anniversary of the grant date or the next annual meeting of stockholders, whichever is earlier, provided she continues her service on the board.

Industry Context

The grant of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like Gossamer Bio. This compensation structure is designed to attract and retain qualified board members and align their incentives with the long-term performance of the company, which is crucial in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the specific number of options (115,000) and exercise price ($1.36) are unique to this grant, the underlying principle of equity-based compensation for board members is consistent with industry benchmarks for aligning director interests with shareholder value.

Related Party Transactions

• The grant of 115,000 stock options to Sandra Milligan, a Director of Gossamer Bio, Inc., constitutes a related party transaction as it involves an insider (director) and the company.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but it also serves to align the director's interests with shareholder value creation, potentially benefiting long-term stock performance.
• Employees: No direct impact mentioned, but director compensation practices can indirectly influence overall compensation philosophy.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 25, 2026) or the next annual meeting of stockholders, whichever is earlier, subject to continued board service.

Key Dates

Keywords

SEC Form 4, Gossamer Bio, GOSS, stock options, director compensation, insider transaction, equity grant, beneficial ownership